• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RenovoRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/14/26 4:17:07 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNXT alert in real time by email
    8-K
    false0001574094California00015740942026-05-142026-05-14

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 14, 2026

    RENOVORX, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    001-40738

    27-1448452

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification No.)

    2570 W El Camino Real, Suite 640

    Mountain View, CA

    94040

    (Address of principal executive offices)

    (Zip Code)

    Registrant’s telephone number, including area code: (650) 284-4433

    N/A

    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

    RNXT

    Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


     

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Item 2.02

    Results of Operations and Financial Condition.

    On May 14, 2026, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results as of and for the quarter ended March 31, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No.

    Description

    99.1

    Press Release of RenovoRx, Inc., dated May 14, 2026

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    -2-

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    RENOVORX, INC.

    Date: May 14, 2026

    By:

    /s/ Mark Voll

    Name:

    Mark Voll

    Title:

    Chief Financial Officer

    -3-


    Get the next $RNXT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNXT

    DatePrice TargetRatingAnalyst
    11/1/2021$16.00Buy
    Roth Capital
    10/6/2021$15.00Buy
    Maxim Group
    More analyst ratings

    $RNXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

    MOUNTAIN VIEW, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer, Shaun Bagai, will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, being held June 23-24, 2026. Mr. Bagai will present on Tuesday, June 23rd at 12:30 P.M. ET. A replay will be available on the Company's Investor Relations website after the event at https://ir.renovorx.com/news-events. Mr. Bagai will discuss RenovoRx's record first quarter 2026 rev

    6/4/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

    MOUNTAIN VIEW, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that the U.S. Food and Drug Administration (FDA) recently granted RenovoRx Orphan Drug Designation (ODD) of oxaliplatin for the treatment of pancreatic cancer. The designation was issued by the FDA's Office of Orphan Products Development pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Oxaliplatin is an approved and commonly used chemotherapy. As RenovoRx continues to advan

    5/28/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

    Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects MOUNTAIN VIEW, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that an abstract from a pharmacokinetic (PK) and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial has been published online in connection with the 2026

    5/26/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on RenovoRx with a new price target

    Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00

    11/1/21 11:49:10 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on RenovoRx with a new price target

    Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00

    10/6/21 8:24:28 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Voll Mark bought $19,690 worth of shares (25,000 units at $0.79), increasing direct ownership by 21% to 142,380 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    5/21/26 7:00:14 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bagai Shaun

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    4/7/26 8:00:06 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Voll Mark

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    4/7/26 8:00:05 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by RenovoRx Inc.

    10-K/A - RenovoRx, Inc. (0001574094) (Filer)

    5/15/26 5:25:44 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by RenovoRx Inc.

    10-Q - RenovoRx, Inc. (0001574094) (Filer)

    5/14/26 4:19:28 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RenovoRx, Inc. (0001574094) (Filer)

    5/14/26 4:17:07 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Voll Mark bought $19,690 worth of shares (25,000 units at $0.79), increasing direct ownership by 21% to 142,380 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    5/21/26 7:00:14 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/22/26 7:00:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $8,424 worth of shares (9,795 units at $0.86), increasing direct ownership by 1% to 788,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/5/26 7:00:02 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)

    SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)

    2/14/23 4:51:34 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by RenovoRx Inc.

    SC 13G - RenovoRx, Inc. (0001574094) (Subject)

    4/14/22 2:24:24 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by RenovoRx Inc.

    SC 13G - RenovoRx, Inc. (0001574094) (Subject)

    2/14/22 6:33:04 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Leadership Updates

    Live Leadership Updates

    View All

    $RNXT
    Financials

    Live finance-specific insights

    View All

    RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

    Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced continued commercial progress, with

    2/27/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

    MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more than three decades of financial leadership experience to RenovoRx, with a strong track record for guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as Chief Financial Officer for multiple publicly traded technology co

    2/5/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

    MOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced the appointment of renowned UCLA surgeon and pancreatic disease expert Timothy Donahue, MD, to RenovoRx's scientific advisory board (SAB). Dr. Donahue is a nationally recognized expert in pancreatic cancer and serves as the Director of UCLA's Agi Hirshberg Center for Pancreatic Diseases and as Chief of the Division of Surgical Oncology at the David Geffen School of Medicine. He also holds the Garry Shandling Ch

    11/6/25 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

    Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ Therapy Platform Enabled by the RenovoCath® Device Phase III TIGeR-PaC Trial Advances Toward Completion with Full Enrollment Expected in June 2026 Ended First Quarter with $12.4 million in cash, Sufficient to Fund Operations into at Least the Second Half of 2027 Management to Host Conference Call Today at 4:30 P.M. ET MOUNTAIN VIEW, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncolo

    5/14/26 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

    MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will host its first quarter 2026 financial results and business highlights conference call on May 14, 2026, at 4:30 pm ET. Additional details will be available on the Investor Relations section of the Company's website at https://ir.renovorx.com/. During the call, RenovoRx's management is expected to highlight positive commercial momentum, including progress in achieved sales of RenovoCath as a stan

    4/29/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

    RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its f

    3/30/26 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care